Doxercalciferol
- Generic Name
- Doxercalciferol
- Brand Names
- Hectorol
- Drug Type
- Small Molecule
- Chemical Formula
- C28H44O2
- CAS Number
- 54573-75-0
- Unique Ingredient Identifier
- 3DIZ9LF5Y9
- Background
Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the t...
- Indication
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT02282813
Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Mariana Markell
- Target Recruit Count
- 39
- Registration Number
- NCT00889629
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
- Conditions
- Interventions
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00792857
- Locations
- 🇺🇸
Pivotal Reseach Centers, Peoria, Arizona, United States
🇺🇸Western New England Renal and Transplant Associates, Springfield, Massachusetts, United States
🇺🇸Northeast Clinical Research, Allentown, Pennsylvania, United States
Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT00646282
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 111
- Registration Number
- NCT00601107
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Duke University
- Target Recruit Count
- 24
- Registration Number
- NCT00528788
- Locations
- 🇺🇸
Duke University Medical Center Dialysis Unit, Durham, North Carolina, United States
Doxercalciferol in Recurrent Pediatric Solid Tumors
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00511017
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT00285467
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.